Saudi SFDA launches NADR program to accelerate rare disease drug development
RIYADH — The Saudi Food and Drug Authority (SFDA) has launched the New Accelerator Program for Drugs in Rare Diseases (NADR) to support the development of and access to medicines for rare diseases. Operating within the SFDA’s regulatory framework, NADR is a specialized initiative aimed at streamlining the development, evaluation, and authorization of drugs for rare diseases. The program also…
We haven't written up this one. Saudi Gazette has the full story — the link below goes straight to it.
